While it appears that people with attention deficit hyperactivity disorder (ADHD) are more likely to develop Parkinson’s disease later in life than are individuals without the neurodevelopmental disorder, further proof is needed to establish a link, according to a new systematic review. “Our review provides preliminary results that a…
Motor abilities assessed via multiple sensors on a smartwatch correlated well with motor function as rated by clinicians, and could distinguish between “on” and “off” medication states for Parkinson’s disease patients, according to a study in Japan. “This study has shown that wearable devices can provide reliable and objective…
Asha Therapeutics has been selected as a Blue Knight company, joining a public-private initiative that focuses on speeding new technology and science to help quickly and effectively deal with emerging dangers to public health and safety. The biopharmaceutical company’s selection was prompted by its proprietary therapeutic design platform, known…
Future Leaders in Canadian Brain Research, a Brain Canada program, has awarded two early-career scientists CA$100,000 (about $74,180) each in grants to advance research projects into Parkinson’s disease. Maria Ioannou, PhD, an assistant professor of physiology at the University of Alberta, is exploring alpha-synuclein protein clumping, a hallmark…
The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Inbrain Neuroelectronics’ neural platform for its potential to provide more effective deep brain stimulation (DBS) as an add-on Parkinson’s treatment. The platform — called Intelligent Network Modulation System — combines skin-like graphene material and artificial…
Measuring levels of an enzyme called DOPA decarboxylase (DDC) in the blood or fluid around the brain and spinal cord may help distinguish Parkinson’s disease and related disorders from non-Parkinsonian neurodegenerative diseases, a study reports. “Since the symptoms of various neurodegenerative brain diseases resemble each other, there is a…
When the alpha-synuclein protein is present at high concentrations around cellular membranes, it lifts up rather than lying flat against the membrane, making it more prone to clumping, a study shows. The finding may offer insight into the molecular mechanisms that drive Parkinson’s disease, where toxic clumps of alpha-synuclein…
Michael J. Fox has received the 2023 Elevate Prize Catalyst Award in recognition of his work with the Michael J. Fox Foundation for Parkinson’s Research (MJFF), an organization dedicated to developing better treatments, and eventually, finding a cure for the Parkinson’s disease. Granted by the Elevate Prize…
Dopamine-making neurons — whose loss characterizes Parkinson’s disease — produce thousands of circular RNA molecules that, beyond their normal duties, may play a role in neurodegenerative diseases, a study reports. “Circular RNA has long been cast aside as junk, but we believe it has an important role in programming…
Note: This story was updated Sept. 20, 2023, to reflect that Acadia is working on Nuplazid’s development as a treatment for schizophrenia. The U.S. Food and Drug Administration (FDA) has updated the prescribing label for Nuplazid (pimavanserin) — an approved therapy for Parkinson’s disease-related hallucinations and delusions…
Get regular updates to your inbox.
